Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter assessment of transdermal therapy in overactive bladder with oxybutynin TDS (MATRIX).

Trial Profile

Multicenter assessment of transdermal therapy in overactive bladder with oxybutynin TDS (MATRIX).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms MATRIX
  • Most Recent Events

    • 22 Sep 2011 Actual end date (May 2005) added as reported by ClinicalTrials.gov.
    • 10 Apr 2007 Status change
    • 10 Apr 2007 Status changed from in progress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top